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case report
Incidental mild hyperglycemia 
in children: two MODY 2 families 
identified in Brazilian subjects   
Hiperglicemia incidental em crianças: duas famílias 
com MODY 2 identificadas em brasileiros 
Lílian A. Caetano1,2, Alexander A. L. Jorge1, Alexsandra C. Malaquias1, 
Ericka B. Trarbach1, Márcia S. Queiroz2, Márcia Nery2, Milena G. Teles1,2
SUMMARY
Maturity-onset diabetes of the young (MODY) is characterized by an autosomal dominant mode 
of inheritance, early onset of hyperglycemia, and defects of insulin secretion. MODY subtypes 
described present genetic, metabolic, and clinical differences. MODY 2 is characterized by mild 
asymptomatic fasting hyperglycemia, and rarely requires pharmacological treatment. Hence, 
precise diagnosis of MODY is important for determining management and prognosis. We report 
two heterozygous GCK mutations identified during the investigation of short stature. Case 1: a 
prepubertal 14-year-old boy was evaluated for constitutional delay of growth and puberty. During 
follow-up, he showed abnormal fasting glucose (113 mg/dL), increased level of HbA1c (6.6%), and 
negative β-cell antibodies. His father and two siblings also had slightly elevated blood glucose le-
vels. The mother had normal glycemia. A GCK heterozygous missense mutation, p.Arg191Trp, was 
identified in the proband. Eighteen family members were screened for this mutation, and 11 had 
the mutation in heterozygous state. Case 2: a 4-year-old boy investigated for short stature revealed 
no other laboratorial alterations than elevated glycemia (118 mg/dL); β-cell antibodies were nega-
tive. His father, a paternal aunt, and the paternal grandmother also had slightly elevated glycemia, 
whereas his mother had normal glycemia. A GCK heterozygous missense mutation, p.Glu221Lys, 
was identified in the index patient and in four family members. All affected patients had mild 
elevated glycemia. Individuals with normal glycemia did not harbor mutations. GCK mutation 
screening should be considered in patients with chronic mild early-onset hyperglycemia, family 
history of impaired glycemia, and negative β-cell antibodies. Arq Bras Endocrinol Metab. 2012;56(8):519-24
SUMÁRIO
O diabetes do tipo MODY (maturity-onset diabetes of the young) caracteriza-se por herança autos-
sômica dominante, início precoce da hiperglicemia e defeitos na secreção de insulina. Os subtipos 
de MODY apresentam diferenças genéticas, metabólicas e clínicas. O MODY 2 é caracterizado por 
hiperglicemia leve assintomática e raramente requer tratamento farmacológico. O diagnóstico pre-
ciso de MODY é importante para se determinar o tratamento e o prognóstico. Relatamos duas mu-
tações no gene GCK em heterozigose identificadas durante investigação de baixa estatura. Caso 
1: paciente do sexo masculino, com 14 anos, pré-púbere, avaliado por atraso constitucional do 
crescimento e da puberdade. Durante o acompanhamento, apresentou glicemia de jejum alterada 
(113 mg/dL), aumento de HbA1c (6,6%) e anticorpos anticélulas β negativos. Seu pai e dois irmãos 
também apresentavam glicemia levemente elevada. A mãe tinha glicemia normal. Foi identificada 
no gene GCK uma mutação missense em heterozigose, p.Arg191Trp. Dezoito membros da família 
foram rastreados e 11 apresentavam essa mutação. Caso 2: paciente do sexo masculino, com 4 
anos, em avaliação por baixa estatura. Não apresentou alterações laboratoriais, exceto por glice-
mia elevada (118 mg/dL). Anticorpos anticélulas β foram negativos. Seu pai, uma tia paterna e a avó 
paterna também apresentavam glicemia discretamente elevada, e a mãe, glicemia normal. A mu-
tação missense em heterozigose, p.Glu221Lys, foi identificada no paciente-índice e em 4 membros 
da família. Todos os pacientes afetados apresentavam hiperglicemia leve. Essas mutações não fo-
ram identificadas nos indivíduos com glicemia normal. O rastreamento de mutações no gene GCK 
deve ser considerado em pacientes com hiperglicemia crônica leve e de início precoce, história fa-
miliar de glicemia elevada e anticorpos anticélulas β negativos. Arq Bras Endocrinol Metab. 2012;56(8):519-24
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INTRODUCTION
Genetic defects affecting only one gene correspond to 1% to 5% of all cases of diabetes mellitus (DM) 
(1,2). Different genes related to monogenic diabetes 
have been identified and are associated with maturity-
onset diabetes of the young (MODY), neonatal dia-
betes, mitochondrial diabetes, mutations in the insu-
lin receptor (insulin resistance syndromes), and other 
genetic syndromes associated to diabetes (e.g. Wolfram 
syndrome) (3). A number of cases of monogenic diabe-
tes are erroneously classified as type 1 or type 2 diabetes 
(4,5). It is estimated that close to 5% of the individuals 
classified as having type 2 DM, and about 10% of those 
considered type 1 DM, are actual carriers of a MODY 
mutation (6). 
MODY is the most common form of monogenic 
diabetes, also known as familial diabetes (7). It is 
characterized by autosomal dominant mode of in-
heritance, early onset of hyperglycemia (usually be-
fore 25 years old) (2,8), defects of insulin secretion 
(3), and generally lack of beta-cell specific antibod-
ies (2,8). Mutations occurring in MODY genes lead 
to a profound phenotypic impact (high penetrance), 
and 95% of the individual carriers of a MODY mu-
tation will be diabetic or will have altered glycemic 
metabolism before the age of 55 (6). To date, there 
are eleven types of MODY described, distinguished 
by genetic, metabolic, and clinical heterogeneity. 
Mutations in the genes HNF4A, GCK, HNF1A, 
PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, 
INS, BLK are associated with MODY 1 to 11, re-
spectively (4). The prevalence of MODY varies 
among different countries and the most common 
forms are type 2 and 3 (4). The largest series de-
scribed so far are in France and England (6). MODY 
2 is the most frequent form in France and may ac-
count for 50 to 60% of cases (9,10). MODY 3 is 
the most prevalent type in British families, account-
ing for 52 to 63% of cases (5,11). Differences in 
the prevalence of MODY 2 and MODY 3 are likely 
associated with the different ways of ascertainment 
(evaluation in pediatric or adult clinics, self-reported 
diabetes, new diagnosis of hyperglycemia through a 
familial survey; recruitment from outpatient clinics) 
(8). The prevalence of the different types of MODY 
in Brazil was evaluated in a total of 48 probands in 3 
studies. Among identified mutations, MODY 3 was 
the most common type, followed by MODY 2 (only 
few reported variants). MODY 2 and 3 mutations 
did not explain the majority of MODY cases in the 
Brazilian population, which resulted in a high prev-
alence of MODY X (no known mutation), ranging 
from 46.2 to 73.9% of the suspected cases (12-14).
MODY 2 is associated with heterozygous inacti-
vating mutations in the gene GCK, which is locat-
ed on chromosome 7 (7p15.3-p15.1) and consists 
of 12 exons (15). The first mutation was reported 
in 1992 (16), and over 600 different GCK muta-
tions distributed throughout the 10 coding exons 
have been identified so far. There are no muta-
tion hotspots (17). The GCK gene encodes the 
465-amino-acid protein, called glucokinase, which 
is one of four enzymes of the hexokinase family. It 
catalyzes the phosphorylation of glucose to produce 
glucose-6-phosphate as the first step of glycolysis 
(18). Glucokinase plays an important regulatory 
role in glucose metabolism. As a glucose sensor, it 
regulates insulin secretion in pancreatic β-cells by 
changing the glucose phosphorylation rate over a 
range of physiological glucose concentrations (18). 
MODY 2 is characterized by a deficiency in gluco-
kinase, and shows a characteristic mild, often asymp-
tomatic, fasting hyperglycemia (19). Most patients 
have impaired fasting glucose or impaired glucose 
tolerance, and less than 50% of affected individuals 
have overt diabetes (9,20). Diagnosis is usually inci-
dental during childhood, youth, or pregnancy (21). 
An study on incidental hyperglycemia in patients un-
der 18 years old estimated that approximately 15% of 
cases are caused by GCK mutations (22). MODY 2 
patients show a small increment in the 2-hour glu-
cose value observed in the oral glucose tolerance test, 
which usually is less than 60 mg/dL (23). In most 
cases of MODY 2, patients require no pharmacologi-
cal treatment, and are managed on diet alone. Those 
patients commonly have no diabetes-related complica-
tions (8,24). Hence, precise recognition of this disor-
der is very important for treatment decisions, and has 
relevant prognostic value (25). Accurate diagnosis can 
only be made by molecular genetic testing (24,26). 
We report two heterozygous GCK mutations 
identified during investigation of short stature in 
two young boys with persistent mild hyperglycemia. 
These two substitutions have never been reported in 
the Brazilian population.
Hyperglycemia in children: MODY 2
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CASE REPORTS
Case 1
A prepubertal 14-year-old boy with height of 130 cm 
(-3.5 SD) and weight of 25.5 kg was evaluated for con-
stitutional delay of growth and puberty. During follow-
up, he started puberty at the age of 16, and his adult 
height was 161 cm. Laboratory evaluation showed im-
paired fasting glucose [113 – 124 mg/dL (6.3 – 6.9 
mmol/L)], and increased A1C levels (5.9% – 6.6%). 
Serum anti-GAD, anti-IA2, anti-IAA were negative. 
Oral glucose tolerance test showed an increase of 35 
mg/dL in glucose level after 2 h (Table 1). His father 
also had slightly elevated blood glucose levels, as well as 
two siblings. A total of eighteen family members were 
screened. Eleven of them had impaired fasting glucose 
levels. Follow-up evaluations of this patient and some 
family members (who were enrolled in our outpatient 
clinic) were conducted over more than a decade after 
the initial appointment, and revealed that glycemia have 
not changed considerably. In addition, screening for 
retinopathy and nephropathy were negative (Table 1). 
Case 2
A 4-year-old boy with 95 cm (-1.5 SD) and 15.8 kg. 
During follow-up (3 years), he remained in the fifth 
percentile in the growth chart, and laboratory tests 
revealed no alterations other than mild hyperglycemia 
[118 – 123 mg/dL (6.6 – 6.8 mmol/L)]. β-cell anti-
bodies were negative (Table 1). His father, a paternal 
aunt, a paternal cousin, and the paternal grandmother 
also had slightly elevated glycemia, whereas his mother 
had normal glycemia. The proband and these four fam-
ily members with impaired fasting glucose were recruit-
ed for genetic evaluation. Follow-up of this patient and 
his father is shown in table 1, emphasizing glycemia 
stability.
Table 1. Clinical and laboratory characterization of patients with MODY 2
Family 1 Family 2
Proband Father Sister Cousin Proband Father
GCK mutation p.R191W p.E221K
Gender Male Male Female Female Male Male
Birth weight (g) 2450 NA NA NA 2775 NA
At diagnosis
Age (years) 14 42 14 8 4 35
BMI (kg/m2) 15.1A 17.5 25.7B 15.0C 17.5B 25.8
Fasting glucose level (mg/dL) 113 126 112 128 118 128
Fasting insulin level (µU/mL) 2.9 4.9 5.3 8.6 2.0 9.0
Fasting C-peptide level (ng/mL)D 1.7 1.0 1.1 0.9  2.08 2.3
A1C level (%)E 5.9 6.6 6.5 6.5 6.5 7.6
OGTT: basal glucose level (mg/dL) 120 141 NA 137 NA 134
OGTT: 2-hour postload glucose level (mg/dL) 155 146 NA 203 NA 181
β-cell antibodies Negative Negative NA Negative Negative Negative
Follow-up
Duration of follow-up (years) 15 12 12 11 3 3
Range of fasting glucose levels (mg/dL) 113 - 124 119 - 147 104 - 140 97 - 129 118 -123 120 - 134 
Range of fasting insulin levels (µU/mL) 2.9 - 4.6 2.5 - 4.2 5.3 - 16.9 NA 2.0 - 4.0 NA
Range of fasting C-peptide levels (ng/mL) 0.9-1.3D; 1.7F 1.0D; 1.2F 1.9 - 2.9F NA NA NA
Range of A1C levels (%)G 5.9 - 6.6 6.5 - 7.4 5.5 - 6.8 5.9 - 6.6 NA 7.0 - 7.6
Microalbuminuria Negative Negative NA Negative NA Negative
Fundoscopic examination Normal Normal NA Normal NA Normal
BMI: body mass index; OGTT: oral glucose tolerance test; NA: not available. 
β-cell antibodies: glutamic acid decarboxylase (GAD) antibody; tyrosine phosphatase antibody (IA2); insulin antibody (IAA).
BMI Percentile for age and sex: A less than the 5th percentile, B between the 85th and the 95th percentile, C between the 5th and the 50th percentile, 
Laboratory normal range (NR): fasting glucose: NR 70 – 99 mg/dL; fasting insulin: NR < 25 µU/mL; 2-hour postload glucose: NR < 140 mg/dL;
D Fasting C-peptide by immunofluorometric assay (NR 0.4 – 3.6 ng/mL); E A1C by boronate affinity chromatography, and ion-capture assay (NR 5.5 – 8.5%); F Fasting C-peptide by 
immunochemiluminometric assay (NR 1.1 – 4.4 ng/mL); G A1C by high performance liquid chromatography – HPLC (NR 4.1 – 6%).
Hyperglycemia in children: MODY 2
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SUBJECTS AND METHODS
Patients were selected from the Endocrinology Divi-
sion Outpatient Clinic of Sao Paulo Clinical Hospital, 
Sao Paulo Medical School, Universidade de São Paulo 
(USP), Brazil. 
Laboratory tests were carried out by standard 
methodology in the clinical laboratory of the hospi-
tal. Plasma glucose (fasting and 2-hour postload) was 
performed using automated colorimetric enzymatic 
method (fasting plasma glucose: normal range 70 – 
99 mg/dL; 2-hour postload glucose level: normal 
range < 140 mg/dL). HbA1C was initially measured 
by boronate affinity chromatography, and ion-cap-
ture assay (normal range 5.5% – 8.5%); and by high 
performance liquid chromatography – HPLC (nor-
mal range 4.1% – 6%) since 2006; this method is cer-
tified by the National Glycohemoglobin Standard-
ization Program – NGSP. Insulin was measured by 
immunofluorometric assay (fasting normal range < 
25 µU/mL). Fasting serum C-peptide was measured 
initially by immunofluorometric assay (normal range 
0.4 – 3.6 ng/mL), and more recently, by electroche-
miluminescence (normal range 1.1 – 4.4 ng/mL). 
β-cell antibodies were evaluated by radioimmuno-
assay: glutamic acid decarboxylase (GAD) antibody 
(normal range < 25 U/mL); tyrosine phosphatase 
(IA2) antibody (normal range < 125 U/mL); insulin 
(IAA) antibody (normal range < 0.4 U/mL). 
Diabetes-related microvascular complications 
were screened: nephropathy was evaluated by micro-
albuminuria, which was measured by immunoneph-
elometric assay, and retinopathy was assessed by fun-
doscopic examination through a dilated pupil.
Genomic DNA was extracted from peripheral-
blood leukocytes, and the entire coding regions, as 
well as the exon-intron boundaries of the GCK gene 
were amplified by polymerase chain reaction (PCR). 
Genotyping was performed using automated se-
quencing. 
The present study was approved by the Ethics 
Committee of the hospital. Informed consent was 
obtained from the patients or their parents.
RESULTS
Molecular GCK sequence analysis of the first in-
dex patient revealed a heterozygous missense muta-
tion CGG>TGG in exon 5, nucleotide position 571 
(c.571C>T), causing a change of the amino acid ar-
ginine to tryptophan (p.Arg191Trp) (Figure 1). The 
father also harbors this mutation, but not the mother, 
who does not have hyperglycemia. A total of 18 fam-
ily members were screened for p.Arg191Trp mutation, 
and 11 had the mutation in heterozygous state. All af-
fected patients had mild elevated glycemia, and fam-
ily members with normal glycemia did not harbor the 
mutation (Figure 2). 
GCK sequencing of the second proband identi-
fied a heterozygous missense mutation GAG>AAG 
in exon 6, nucleotide position 661 (c.661G>A), 
changing the amino acid glutamic acid to lysine 
(p.Glu221Lys) (Figure 1). Molecular analysis of all 
family members with hyperglycemia revealed the 
same mutation (Figure 2). 
Figure 1. Schematic representation of exons 1 to 10 of glucokinase gene, 
located in the short arm of chromosome 7. Arrows indicate the mutations 
identified in this study (first report in Brazilian families). 
Chromosome 7p15.3-p15.1
1a 1b 1c 2 3 4 5 6 7 8 9 10
c.571C>T
p.R191W
c.661G>A
p.E221K
Hyperglycemia in children: MODY 2
Figure 2. (A) Pedigree of Family 1. (B) Pedigree of Family 2. Arrows 
identify the probands. Squares denote male family members, and circles 
denote females. Question marks (?) denote family members with unknown 
glycemic status, and that were not genotyped. Individuals shown in white 
had normal glycemia and did not harbor the mutation (wild type GCK), and 
those shown in black had hyperglycemia and the GCK mutation (MODY 2).
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be considered in patients with chronic asymptomatic 
hyperglycemia, early age of onset, family history of 
impaired glycemia, and negative β-cell antibodies, as 
we observed in the patients described here.
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